https://www.selleckchem.com/pr....oducts/bevacizumab.h
The two groups differed significantly in age, heart failure etiology, baseline LVEF and baseline NT-proBNP. On multivariable analysis, nonischemic heart failure, LVEF 30% and NT-proBNP 1500 pg/mL emerged as independent correlates of favorable response to ARNI therapy. ARNI therapy appears to improve echocardiographic parameters of left and right ventricular function in HFrEF patients above the effect of pre-existing optimal medical management. These effects may be particularly pronounced in patients with nonischemic heart
Like
Comment
Share
